Inhibrx's INBRX-106 Shows Strong 44% ORR and Complete Responses in Phase 2 HNSCC, Doubling PD-1 Monotherapy Efficacy
INBX has more than doubled off its 52-week low of $10.84.
Summary
Inhibrx Biosciences reported highly positive interim Phase 2 data for its drug candidate INBRX-106 in first-line Head and Neck Squamous Cell Carcinoma (HNSCC). The combination of INBRX-106 with pembrolizumab achieved a confirmed overall response rate (ORR) of 44.0%, significantly outperforming pembrolizumab alone which showed 21.4% ORR. The trial also observed three complete radiographic responses and up to a 15-fold increase in systemic T-cell expansion, indicating a strong costimulatory benefit. This robust data for INBRX-106, a distinct asset from the ozekibart program mentioned in the recent 10-K, represents a material positive development for the company, potentially expanding its pipeline value significantly. Traders will be watching for further data updates and progression to later-stage trials, as these results could drive substantial re-rating of the stock.
At the time of this announcement, INBX was trading at $150.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.84 to $155.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.